Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.

@article{Chang1996DoubleblindRS,
  title={Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.},
  author={Alex H. Chang and Beow Yong Yeap and Theresa Davis and Ronald Blum and Richard Hahn and O P Khanna and H P Fisher and Joseph Rosenthal and Robert Witte and Roger Schinella and Donald J. Trump},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 8},
  pages={2250-7}
}
PURPOSE Patients with stage D2 prostate carcinoma are often treated initially with hormones to decrease endogenous testosterone. Therapy with diethylstilbestrol (DES), leuprolide, or bilateral orchiectomy has been reported to be equivalent. DES is the cheapest preparation, but has the potential for serious cardiovascular or thromboembolic complications. Flutamide is a novel antiandrogen with fewer side effects. PATIENTS AND METHODS The Eastern Cooperative Oncology Group (ECOG) conducted a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…